| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flynn James E | 9.99% | $11.4M | 15.6M | Deerfield Management Company, L.P. | Feb 27, 2025 | |||
| Cystic Fibrosis Foundation | 9.99% | -50% | $1.82M | -$888K | 2.49M | -39.1% | Cystic Fibrosis Foundation | Feb 27, 2025 |
| OrbiMed Israel BioFund GP Limited Partnership | 1% | 276K | ORBIMED ISRAEL GP LTD. | Jun 18, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 159 | $83.00 | $0.52 | 1 | |
| 2025 Q2 | 97K | $42.7K | $0.45 | 2 | |
| 2025 Q1 | 97K | $53.9K | +$88.00 | $0.55 | 2 |
| 2024 Q4 | 96.9K | $70.7K | -$180K | $0.73 | 1 |
| 2024 Q3 | 301K | $307K | -$9.57M | $1.02 | 2 |
| 2024 Q2 | 23.2M | $7.81M | +$3.18M | $0.34 | 11 |
| 2024 Q1 | 13.8M | $6.2M | +$2.6M | $0.45 | 9 |
| 2023 Q4 | 8.09M | $2.26M | -$124K | $0.28 | 13 |
| 2023 Q3 | 7.45M | $2.62M | -$89.9K | $0.35 | 10 |
| 2023 Q2 | 7.71M | $2.77M | +$508K | $0.36 | 10 |
| 2023 Q1 | 6.33M | $1.93M | +$60.6K | $0.31 | 13 |
| 2022 Q4 | 6.16M | $1.15M | -$38.9K | $0.19 | 14 |
| 2022 Q3 | 6.16M | $2.09M | -$3.3K | $0.34 | 14 |
| 2022 Q2 | 6.18M | $4.51M | -$860K | $0.73 | 11 |
| 2022 Q1 | 6.62M | $12.8M | +$118K | $1.93 | 13 |
| 2021 Q4 | 6.56M | $10.5M | -$754K | $1.60 | 13 |
| 2021 Q3 | 6.95M | $21.3M | +$2.59M | $3.06 | 18 |
| 2021 Q2 | 6.09M | $33.3M | -$587K | $5.46 | 14 |
| 2021 Q1 | 6.18M | $44M | -$200K | $7.12 | 14 |
| 2020 Q4 | 4.14M | $26.4M | +$241K | $6.38 | 9 |
| 2020 Q3 | 6.22M | $39.5M | +$657K | $6.34 | 10 |
| 2020 Q2 | 6.12M | $33.8M | +$407K | $5.51 | 12 |
| 2020 Q1 | 6.04M | $42.2M | +$6.04M | $7.00 | 11 |
| 2019 Q4 | 5.16M | $50M | +$28.3M | $9.69 | 8 |
| 2019 Q3 | 100K | $1.02M | +$1.02M | $10.15 | 1 |